Because of various clinical situations, there may be a need for clinicians to transition patients from one anticoagulant therapy to another. In order to do this safely, the pharmacology profiles of both agents should be taken into consideration.
Your search for Warfarin returned 9 results
Arterial and venous thromboembolic disease are often complications associated with nephrotic syndrome (NS) but guidelines are lacking on the management of thrombosis in NS.
A case report in the Journal of Pharmacy Practice is the first published instance of a patient that required >30% reduction in weekly warfarin dose after smoking cessation.
Purpose: The aim of this review is to discuss possible interactions that may occur between warfarin and fruit products. Methods: A literature search was conducted using the search terms: “warfarin (Coumadin®) and fruit interactions, warfarin and fruit, warfarin and fruit juice, case reports and clinical trials”.
Background and Purpose- The aim was to investigate the risk of intracerebral hemorrhage (ICH) in patients with ischemic stroke taking warfarin and whether this risk changed over time. The patients was studied in two 4-year periods (inclusion 2001-2004: follow-up until 2005 and inclusion 2005–2008: follow-up until 2009) for which rates of subsequent ICH were calculated.
Background: Nonvalvular atrial fibrillation (AF) is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. Methods and Results-There were 6229 patients (44%) aged 75 years with AF and 2 stroke risk factors randomized to warfarin (target international normalized ratio 2.0-3.0) or rivaroxaban (20mg daily; 15mg if creatinine clearance…
The influence of warfarin pharmacogenomics on major bleeding risk has been little studied in long-term users and non–specialist care settings. We conducted a case–control study to evaluate associations between CYP2C9*2/*3, VKORC1(1173), and CYP4F2*3 variants and major bleeding among patients treated with warfarin in a community setting.
Background- During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. Methods and Results- In the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition …
Despite current guidelines, many patients with atrial fibrillation (A-fib) and ischemic stroke (IS) are not receiving antithrombotic therapy after hospital discharge or are receiving antiplatelet therapy alone, increasing their risk of major vascular events.